Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity

Gene Therapy
K PalmerJ Gauldie

Abstract

It has been shown that intratumor administration of an adenovirus vector expressing IL-12 produces a potent T cell-mediated response that leads to significant tumor regression in a murine breast cancer model. IP-10 and MIG are CXC chemokines that recruit mononuclear cells in vivo. In addition to their chemotactic roles, IP-10 and MIG inhibit angiogenesis. We tested whether the addition of IP-10 or MIG may both enhance the antitumor immune response of IL-12 through T cell recruitment and inhibit tumor growth through angiostasis. Adenovirus vectors expressing IP-10 or MIG and/or IL-12 were administered intratumorally in a murine model of mammary adenocarcinoma and fibrosarcoma. Administration of IP-10 or MIG in combination with IL-12 resulted in considerable tumor regression and increased survival time of tumor-bearing animals as compared with IP-10, MIG, IL-12 alone or control-treated animals, with the IP-10 IL-12 combination being most effective. These results suggest augmenting the antitumor immune response and inhibiting tumor angiogenesis with adenoviral vectors expressing IP-10 in combination with IL-12 is a novel way to enhance tumor regression.

References

May 5, 1995·Biochemical and Biophysical Research Communications·R M StrieterP J Polverini
Apr 19, 1995·Journal of the National Cancer Institute·E E VoestJ Folkman
Jul 1, 1995·The Journal of Experimental Medicine·A L AngiolilloG Tosato
Nov 1, 1995·The Journal of Experimental Medicine·F LiaoJ M Farber
Feb 1, 1995·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·M J BrundaM K Gately
Aug 29, 1995·Proceedings of the National Academy of Sciences of the United States of America·C L AddisonF L Graham
Oct 1, 1993·The Journal of Experimental Medicine·M J BrundaM K Gately
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·C SgadariG Tosato
Dec 1, 1996·European Journal of Immunology·B GiancarloP Allavena
Aug 1, 1997·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·A A MaghazachiA Al-Aoukaty
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·B M PützerF L Graham
Feb 5, 1998·Nature·P LoetscherJ M Dayer
Sep 17, 1998·Journal of Leukocyte Biology·C KaneganeG Tosato
Oct 2, 1998·Advances in Immunology·G Trinchieri
Dec 22, 1998·The Journal of Experimental Medicine·K HungH Levitsky
Jun 15, 1999·Toxicologic Pathology·B D CarT D Anderson
Nov 24, 1999·Immunological Reviews·J Schlom, J W Hodge
Jan 19, 2000·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·K PalmerJ Gauldie
Feb 22, 2000·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·A MelcherR Vile

❮ Previous
Next ❯

Citations

Oct 19, 2013·Cancer Immunology, Immunotherapy : CII·Giorgio MauriMario Paolo Colombo
Oct 8, 2005·Angiogenesis·Charlotta Dabrosin
Oct 4, 2006·Cancer Metastasis Reviews·A Ben-Baruch
Jul 4, 2012·Journal of Molecular Histology·Qingchao ZhuYu Wang
Oct 14, 2009·Molecular and Cellular Biochemistry·Sahdeo PrasadBharat B Aggarwal
Mar 27, 2002·Nature Reviews. Immunology·Bernhard HomeyAlbert Zlotnik
Sep 17, 2008·Pharmacogenetics and Genomics·Keith SextonKelly A BéruBé
Feb 19, 2009·Pigment Cell & Melanoma Research·Ann RichmondYingjun Su
Jan 1, 2009·Immunotherapy·Trina J Stewart, Mark J Smyth
Sep 6, 2012·Immunotherapy·Elham Mohit, Sima Rafati
Mar 14, 2002·Biochemical and Biophysical Research Communications·Ching-Shwun LinTom F Lue
Feb 12, 2014·Cancer Immunology, Immunotherapy : CII·Witold LasekMarek Jakobisiak
Oct 27, 2007·Expert Opinion on Biological Therapy·Jonathan M WeissRobert H Wiltrout
Feb 26, 2008·Expert Opinion on Biological Therapy·Karin JöhrerRichard Greil
Feb 6, 2009·Biotechnology Progress·Kim S Jones
Jun 29, 2004·Biochemical and Biophysical Research Communications·Jun-Qing GuoShang-You You
Mar 3, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Barrett J Rollins
Sep 6, 2002·The American Journal of Pathology·Charlotta DabrosinJack Gauldie
Oct 2, 2013·Oncoimmunology·Christel DevaudMichael H Kershaw
Apr 23, 2005·Immunity·Amanda MurphyMichael H Kershaw
Mar 6, 2012·Leukemia Research·Domenico Ribatti
Sep 6, 2014·Cell Death and Differentiation·S TuguesB Becher
May 15, 2003·International Reviews of Immunology·Mark S Brault, Robert A Kurt
May 16, 2007·Cancer·Pier A RuffiniMassimo Cristofanilli
Oct 16, 2004·Cancer Gene Therapy·Loren W NoblittSuresh K Mittal
Jun 6, 2003·The Journal of Clinical Endocrinology and Metabolism·Charlotta Dabrosin
May 9, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·S GyorffyJ Gauldie
Mar 23, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Cristiana GuiducciMario P Colombo
Feb 23, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Amit A LugadeEdith M Lord
Feb 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anton V GorbachevRobert L Fairchild
Jul 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard J WongYuman Fong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.